Attached files

file filename
EX-99 - EXHIBIT 99.1 - HUTCHINSON TECHNOLOGY INCexh_991.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

March 07, 2011
Date of report (Date of earliest event reported)
 
HUTCHINSON TECHNOLOGY INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
 
Minnesota
 
001-34838
 
41-0901840
(State of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
 
40 West Highland Park Drive N.E.,
Hutchinson, Minnesota
 
 
 
55350
(Address of Principal Executive Offices)
 
(Zip Code)

(320) 587-3797
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):
 
[   ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
Item 8.01
Other Events.
 
On March 7, 2011, we issued a press release regarding the FDA clearance of our InSpectra StO2 Spot Check, which is filed as Exhibit 99.1 hereto.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)           Exhibits
 
 
99.1
Press Release dated March 7, 2011 regarding the FDA clearance of our InSpectra StO2 Spot Check
 

 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
HUTCHINSON TECHNOLOGY INCORPORATED
   
   
Date:           March 7, 2011
/s/ David P. Radloff
David P. Radloff
Vice President and Chief Financial Officer


 
 

 

EXHIBIT INDEX

No.
 
Description
 
Manner of Filing
         
99.1
 
Press Release dated March 7, 2011 regarding the FDA clearance of our InSpectra StO2 Spot Check
 
Filed Electronically